Pfueller S L, Weber S, Lüscher E F
J Immunol. 1977 Feb;118(2):514-24.
Aggregated IgG coupled covalently with bis-diazobenzidine (BDB-IgG) and labeled with 3H-diazobenzene (3H-BDB-IgG) has been used to study the binding of soluble IgG aggregates to human platelets in relationship to the release of the contents of intracellular granules (e.g., serotonin). In washed cell suspensions a minimum of 0.14 to 0.2 mug 3H-BDB-IgG per 5 X 10(8) platelets (40 to 70 aggregates per cell) was required for the triggering of the release reaction and cell aggregation. Binding was independent of divalent cations. The Arrhenius plot gave a straight line between 0 to 37 degrees C and a Q10 of 1.6. Neither inhibitors of the release reaction nor energy metabolism, nor formaldehyde fixation of the platelets affected binding. Bound 3H-BDB-IgG was not significantly eluted by IgG, bovine albumin (BSA), buffer, or plasma. Binding to washed platelets was more strongly inhibited by human IgG than by F(ab')2, bovine IgG, human albumin (HSA), or BSA. Plasma was an even more effective inhibitor of both binding and release. Plasma deficient in IgG or depleted of complement retained its inhibitory capacity. In the presence of plasma, at physiologic ratios of plasma and platelets, no release of serotonin was observed. Binding, although inhibited in rate, nevertheless occurred. It was enhanced by divalent cation chelation and had a Q10 of 2.5. The release reaction of washed platelets to which 3H-BDB-IgG had been bound in the presence of HSA or BSA was also inhibited by the subsequent addition of plasma or plasma proteins (human IgG being more effective than bovine IgG, F(ab')2, HSA, or BSA). 3H-BDB-IgG bound in the presence of either plasma or human IgG did not induce release when the platelets were subsequently suspended in media lacking these proteins. Thus, it appears that the platelet Fc receptor binds 3H-BDB-IgG by a process which is effectively inhibited by plasma, or by free IgG with an intact Fc, and to some extent by high concentrations of other proteins. The effects of bound IgG aggregates are dependent on the other proteins present both during binding and subsequently added. The mechanism of such receptor modulation and its implications in vivo are discussed.
已使用与双偶氮联苯胺共价偶联的聚集IgG(BDB-IgG)并标记有3H-偶氮苯(3H-BDB-IgG)来研究可溶性IgG聚集体与人血小板的结合与细胞内颗粒(如5-羟色胺)内容物释放的关系。在洗涤过的细胞悬液中,每5×10⁸个血小板(每个细胞40至70个聚集体)至少需要0.14至0.2微克3H-BDB-IgG才能触发释放反应和细胞聚集。结合不依赖于二价阳离子。阿累尼乌斯曲线在0至37℃之间呈直线,Q₁₀为1.6。释放反应抑制剂、能量代谢抑制剂或血小板的甲醛固定均不影响结合。结合的3H-BDB-IgG不会被IgG、牛血清白蛋白(BSA)、缓冲液或血浆显著洗脱。与洗涤过的血小板的结合被人IgG抑制的程度比被F(ab')₂、牛IgG、人白蛋白(HSA)或BSA更强。血浆对结合和释放都是更有效的抑制剂。缺乏IgG或补体耗尽的血浆保留其抑制能力。在血浆存在下,在血浆和血小板的生理比例下,未观察到5-羟色胺的释放。结合虽然速率受到抑制,但仍会发生。它通过二价阳离子螯合而增强,Q₁₀为2.5。在HSA或BSA存在下已结合3H-BDB-IgG的洗涤过的血小板的释放反应也会被随后添加的血浆或血浆蛋白(人IgG比牛IgG、F(ab')₂、HSA或BSA更有效)抑制。当血小板随后悬浮在缺乏这些蛋白质的培养基中时,在血浆或人IgG存在下结合的3H-BDB-IgG不会诱导释放。因此,似乎血小板Fc受体通过一种过程结合3H-BDB-IgG,该过程被血浆或具有完整Fc的游离IgG有效抑制,并在一定程度上被高浓度的其他蛋白质抑制。结合的IgG聚集体的作用取决于结合期间以及随后添加的其他蛋白质。讨论了这种受体调节的机制及其在体内的意义。